AstraZeneca PLC — TRUQAP (capivasertib) in combination with ab · PTEN-deficient metastatic hormone-sensitive prosta.
Run-up into the decision (T-120 → T+5)
Daily close, T-120 (12/26/25) through T+5. Run-up high $209.48 on 2/19/26, low $176.28 on 6/3/26 (T-120 to T-1). FDA decision 6/12/26. Historical price action, not a forecast.
Key facts
FDA decision date2026-06-12
OutcomeApproved
Drug / candidateTRUQAP (capivasertib) in combination with ab